MedTrace Logo

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

NCT02338479 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 340

Last updated 2023-02-08

No results posted yet for this study

Summary

This is a prospective non-therapeutic study, assessing the long-term toxicity of pediatric HCT for hematologic malignancies. This study is a collaboration between the Pediatric Blood and Marrow Transplant Consortium (PBMTC), the Center for International Blood and Marrow Transplant Research (CIBMTR), the National Marrow Transplant Program (NMDP) and the Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI-BMT) of the CIBMTR. The study will enroll pediatric patients who undergo myeloablative HCT for hematologic malignancies at PBMTC sites.

Conditions

  • Acute Lymphoblastic Leukemia/Lymphoma
  • Myelodysplasia
  • Acute Myelogenous Leukemia
  • Juvenile Myelomonocytic Leukemia
  • Chronic Myelogenous Leukemia

Sponsors & Collaborators

Principal Investigators

  • Christine Duncan, MD · Dana-Farber Cancer Institute

  • K. Scott Baker, MD · Fred Hutchinson Cancer Center

Eligibility

Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-09-30
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338479 on ClinicalTrials.gov